National Institutes of Health Consensus Development Conference Statement: adjuvant therapy for breast cancer, November 1-3, 2000.
By P. Eifel, Axelson Ja, J. Costa, J. Crowley, Walter J. Curran, A. Deshler, S. Fulton, Hendricks Cb, M. Kemeny, A. Kornblith and 4 more. Journal of the National Cancer Institute, 2001
908 citations recorded by the source corpus.
Subfields: Cancer Research, Genetics, Public Health, Environmental and Occupational Health
View Paper: https://www.semanticscholar.org/paper/db673514dfd3e82667a875524de73056a0d1f03b
How researchers see this paper
The researchers whose trusted networks rank it highest, strongest advocate first. Every researcher gets a different order.
In Cancer Research
In Genetics
Citations in the corpus
- Predicting the prognosis of breast cancer by integrating clinical and microarray data with Bayesian networks (2006, methodology): “…with the 70 genes model and with the following indices: the St. Gallen consensus (Goldhirsch et al. (1998)), the National Institute of Health (NIH) index (Eifel et al. (2001)) and following (Edén et al. (2004)) also with the widely used Nottingham Prognostic Index (NPI) (Blamey et al. (1979)).”
- Ki-67 as prognostic marker in early breast cancer: a meta-analysis of published studies involving 12 155 patients (2007, background): “…still not considered as an established factor to be used in clinical practice, probably because most of the studies are retrospective and because some uncertainty remains on the way Ki-67 should be assessed (Eifel et al, 2001; Goldhirsch et al, 2003; Colozza et al, 2005; Urruticoechea et al, 2005).”
- The descriptive epidemiology of female breast cancer: an international comparison of screening, incidence, survival and mortality. (2012, neutral): “Clinical guidelines for the use of systemic adjuvant therapy were subsequently developed [96].”